{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:48:56Z","timestamp":1789858136980,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s00431-017-2960-6","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T22:43:05Z","timestamp":1500504185000},"page":"1147-1153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Biologics in juvenile idiopathic arthritis: a narrative review"],"prefix":"10.1007","volume":"176","author":[{"given":"Federica","family":"Vanoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Minoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Malattia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,20]]},"reference":[{"key":"2960_CR1","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","volume":"360","author":"I Aksentijevich","year":"2009","unstructured":"Aksentijevich I, Masters SL, Ferguson PJ et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360:2426\u20132437","journal-title":"N Engl J Med"},{"issue":"9","key":"2960_CR2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10067-011-1720-7","volume":"30","author":"EI Alexeeva","year":"2011","unstructured":"Alexeeva EI, Valieva SI, Bzarova TM et al (2011) Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 30(9):1163\u20131172","journal-title":"Clin Rheumatol"},{"key":"2960_CR3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.autrev.2012.10.021","volume":"12","author":"F Atzeni","year":"2013","unstructured":"Atzeni F, Talotta R, Salaffi F et al (2013) Immunogenicity and autoimunity during anti TNF therapy. Autoimmun Rev 12:703","journal-title":"Autoimmun Rev"},{"issue":"4","key":"2960_CR4","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","volume":"64","author":"T Beukelman","year":"2012","unstructured":"Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD (2012) Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64(4):1263\u20131271","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2960_CR5","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","volume":"64","author":"T Beukelman","year":"2012","unstructured":"Beukelman T, Xie F, Chen L et al (2012) Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64(8):2773\u20132780","journal-title":"Arthritis Rheum"},{"key":"2960_CR6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/RHU.0b013e318205092d","volume":"17","author":"N Bruck","year":"2001","unstructured":"Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F (2001) Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 17:23\u201327","journal-title":"J Clin Rheumatol"},{"key":"2960_CR7","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1002\/art.38569","volume":"66","author":"H Brunner","year":"2014","unstructured":"Brunner H, Ruperto N, Tzaribachev N et al (2014) A148: a multi-center, double-blind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results. Arthritis Rheum 66:S191\u2013S192","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2960_CR8","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","volume":"74","author":"HI Brunner","year":"2015","unstructured":"Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-P\u00e9rez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, G\u00e1mir ML, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F, Paediatric Rheumatology International Trials Organisation PRINTO; Pediatric Rheumatology Collaborative Study Group (PRCSG) (2015) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74(6):1110\u20131117","journal-title":"Ann Rheum Dis"},{"key":"2960_CR9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00148581-200406030-00001","volume":"6","author":"R Carrasco","year":"2004","unstructured":"Carrasco R, Smith JA, Lovell D (2004) Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs 6:137\u2013146","journal-title":"Paediatr Drugs"},{"key":"2960_CR10","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F Benedetti De","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2385\u20132395","journal-title":"N Engl J Med"},{"key":"2960_CR11","first-page":"203","volume":"25","author":"F Benedetti De","year":"1998","unstructured":"De Benedetti F, Martini A (1998) Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 25:203\u2013207","journal-title":"J Rheumatol"},{"key":"2960_CR12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00002281-199709000-00009","volume":"9","author":"F Benedetti De","year":"1997","unstructured":"De Benedetti F, Ravelli A, Martini A (1997) Cytokines in juvenile rheumatoid arthritis. Curr Opin Rheumatol 9:428\u2013433","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"2960_CR13","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","volume":"62","author":"P Diak","year":"2010","unstructured":"Diak P, Siegel J, La Grenade L et al (2010) Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 62(8):2517\u20132524","journal-title":"Arthritis Rheum"},{"key":"2960_CR14","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, Delfino L, Ferlito F, Pelagatti MA, Caroli F, Buoncompagni A, Viola S, Loy A, Sironi M, Vecchi A, Ravelli A, Martini A, Rubartelli A (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58:1505\u20131515","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2960_CR15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00296-009-0942-3","volume":"30","author":"M Halbig","year":"2009","unstructured":"Halbig M, Horneff G (2009) Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int 30(2):229\u2013238","journal-title":"Rheumatol Int"},{"issue":"suppl 2","key":"2960_CR16","first-page":"114","volume":"73","author":"G Horneff","year":"2014","unstructured":"Horneff G, Becker I, On behalf of German and Austrian Collaborative BIKER study group (2014) Serious infections in juvenile idiopathic arthritis patients upon TNF inhibitors depend on disease activity. Arthritis Rheum 73(suppl 2):114\u2013115","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2960_CR17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jbspin.2015.04.020","volume":"3","author":"A Hoxha","year":"2016","unstructured":"Hoxha A, Calligaro A, Tonello M, Ramonda R, Carletto A, Paolazzi G, Bortolotti R, Del Ross T, Grava C, Boaretto M, Favaro M, Teghil V, Ruffatti A, Punzi L (2016) The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a prospective multicentre study. Joint Bone Spine 3(2):167\u2013171","journal-title":"Joint Bone Spine"},{"key":"2960_CR18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/ncprheum0919","volume":"4","author":"A Kelly","year":"2008","unstructured":"Kelly A, Ramanan AV (2008) A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 4:615\u2013620","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"2","key":"2960_CR19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/ard.61.2.171","volume":"61","author":"DA Kietz","year":"2002","unstructured":"Kietz DA, Pepmueller PH, Moore TL (2002) Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum 61(2):171\u2013173","journal-title":"Ann Rheum"},{"issue":"1","key":"2960_CR20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/s10165-010-0348-9","volume":"21","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Takahashi Y, Yamashita H et al (2011) Benefit and a possible risk of tocilizumab therapy for adult-onset Still\u2019s disease accompanied by macrophage-activation syndrome. Mod Rheumatol 21(1):92\u201396","journal-title":"Mod Rheumatol"},{"issue":"11","key":"2960_CR21","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/rheumatology\/kel301","volume":"45","author":"A Kuek","year":"2006","unstructured":"Kuek A, Hazleman BL, Gaston JH et al (2006) Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology (Oxford) 45(11):1448\u20131449","journal-title":"Rheumatology (Oxford)"},{"key":"2960_CR22","first-page":"i34","volume":"48","author":"HJ Lachmann","year":"2009","unstructured":"Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner J et al (2009) Efficacy and safety of canakinumab (ACZ885), a fully human anti-interleukin-1beta antibody, in cryopyrinassociated periodic fever syndrome: results of a multicenter, randomized, double-blind, phase III study. Rheumatology 48:i34\u2013i35","journal-title":"Rheumatology"},{"key":"2960_CR23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group. N Engl J Med 342:763\u2013769","journal-title":"N Engl J Med"},{"key":"2960_CR24","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","volume":"65","author":"DJ Lovell","year":"2013","unstructured":"Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ (2013) Long-term safety and efficacy of rilonacept in patient with systemic juvenile arthritis. Arthritis Rheum 65:2486\u20132496","journal-title":"Arthritis Rheum"},{"key":"2960_CR25","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","volume":"58","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Reiff A, Ilowite NT et al (2008) Pediatric rheumatology collaborative study group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58:1496\u20131504","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2960_CR26","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810\u2013820","journal-title":"N Engl J Med"},{"key":"2960_CR27","first-page":"79","volume":"3","author":"A Lurati","year":"2005","unstructured":"Lurati A, Teruzzi B, Salmaso A et al (2005) Macrophage activation syndrome (MAS) during anti-IL1 therapy (anakinra) in a patient affected by systemic juvenile arthritis (soJIA): a report and review of the literature. Pediatr Rheumatol 3:79\u201385","journal-title":"Pediatr Rheumatol"},{"issue":"2","key":"2960_CR28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.rdc.2004.01.009","volume":"30","author":"SR Maini","year":"2004","unstructured":"Maini SR (2004) Infliximab treatment of rheumatoid arthritis. Rheum Dis Clin N Am 30(2):329\u2013347","journal-title":"Rheum Dis Clin N Am"},{"issue":"2","key":"2960_CR29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FH et al (2011) Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63(2):545\u2013555","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2960_CR30","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","volume":"201","author":"V Pascual","year":"2005","unstructured":"Pascual V, Allantaz F, Arce E et al (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201(9):1479\u20131486","journal-title":"J Exp Med"},{"key":"2960_CR31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","volume":"25","author":"R Peres-Alvarez","year":"2013","unstructured":"Peres-Alvarez R, P\u00e9rez-de-Lis M, Ramos-Casals M, BIOGEAS study group (2013) Biologic induced autoimmune diseases. Curr Opin Rheumatol 25:56","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"2960_CR32","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390\u2013392","journal-title":"J Rheumatol"},{"issue":"9","key":"2960_CR33","first-page":"2120","volume":"28","author":"S Prahalad","year":"2001","unstructured":"Prahalad S, Bove KE, Dickens D et al (2001) Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 28(9):2120\u20132124","journal-title":"J Rheumatol"},{"issue":"4","key":"2960_CR34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","volume":"48","author":"P Quartier","year":"2003","unstructured":"Quartier P, Taupin P, Bourdeaut F et al (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48(4):1093\u20131101","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2960_CR35","first-page":"401","volume":"30","author":"AV Ramanan","year":"2003","unstructured":"Ramanan AV, Schneider R (2003) Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 30(2):401\u2013403","journal-title":"J Rheumatol"},{"issue":"7","key":"2960_CR36","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/acr.22259","volume":"66","author":"S Ringold","year":"2014","unstructured":"Ringold S et al (2014) Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res 66(7):1063\u20131072","journal-title":"Arthritis Care Res"},{"issue":"10","key":"2960_CR37","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.38092","volume":"65","author":"S Ringold","year":"2013","unstructured":"Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovel DJ, Nigrovic PA, Robinson AB, Vehe RK (2013) Recommendations for the treatment of juvenile idiopathic arthritis. Arthritis & Rheum 65(10):2499\u20132512","journal-title":"Arthritis & Rheum"},{"issue":"8","key":"2960_CR38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00044011-200323080-00003","volume":"23","author":"RF Robinson","year":"2003","unstructured":"Robinson RF, Nahata MC, Hayes JR et al (2003) Quality-of-life measurements in juvenile rheumatoid arthritis patients. Clin Drug Investig 23(8):511\u2013518","journal-title":"Clin Drug Investig"},{"issue":"25","key":"2960_CR39","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P et al (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367(25):2396\u20132406","journal-title":"N Engl J Med"},{"key":"2960_CR40","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R et al (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56:3096\u20133106","journal-title":"Arthritis Rheum"},{"key":"2960_CR41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-P\u00e8rez N, Silva CA et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled withdrawal trial. Lancet 372:383\u2013391","journal-title":"Lancet"},{"issue":"2","key":"2960_CR42","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/art.33342","volume":"64","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Quartier P, Wulffraat N et al (2012) A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 64(2):557\u2013567","journal-title":"Arthritis Rheum"},{"key":"2960_CR43","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/keh658","volume":"44","author":"H Schmeling","year":"2005","unstructured":"Schmeling H, Horneff G (2005) Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 44:1008\u20131011","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"2960_CR44","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1002\/art.27741","volume":"62","author":"JF Simard","year":"2010","unstructured":"Simard JF, Neovius M, Hagelberg S, Askling J (2010) Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 62(12):3776\u20133782","journal-title":"Arthritis Rheum"},{"key":"2960_CR45","doi-asserted-by":"crossref","unstructured":"Tappeiner C, Mesquida M, Ad\u00e1n A, Anton J, Ramanan AV, Carreno E, Mackensen F, Kotaniemi K, de Boer JH, Bou R, de Vicu\u00f1a CG, Heiligenhaus A Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016.","DOI":"10.3899\/jrheum.160231"},{"issue":"4","key":"2960_CR46","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/ard.2006.058248","volume":"66","author":"P Tynjala","year":"2007","unstructured":"Tynjala P, Lindahl P, Honkanen V et al (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66(4):548\u2013550","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2960_CR47","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","volume":"70","author":"P Tynjala","year":"2001","unstructured":"Tynjala P, Vahasalo P, Tarkiainen M et al (2001) Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTEJIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis 70(9):1605\u20131612","journal-title":"Ann Rheum Dis"},{"key":"2960_CR48","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","volume":"47","author":"BW Oosten van","year":"1996","unstructured":"van Oosten BW, Barkhof F, Truyen L et al (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531","journal-title":"Neurology"},{"issue":"4","key":"2960_CR49","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, Wulffraat NM (2014) Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 66(4):1034\u20131043","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"2960_CR50","first-page":"2071","volume":"31","author":"JW Verbsky","year":"2004","unstructured":"Verbsky JW, White AJ (2004) Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 31(10):2071\u20132075","journal-title":"J Rheumatol"},{"issue":"12","key":"2960_CR51","first-page":"2481","volume":"34","author":"PF Vojvodich","year":"2007","unstructured":"Vojvodich PF, Hansen JB, Andersson U et al (2007) Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. J Rheumatol 34(12):2481\u20132485","journal-title":"J Rheumatol"},{"key":"2960_CR52","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Amhara Y, Takei S et al (2008) Efficacy and safety of tocilizumab in patients with systemic onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371:998\u20131006","journal-title":"Lancet"},{"issue":"1","key":"2960_CR53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3899\/jrheum.120583","volume":"40","author":"ME Zannin","year":"2013","unstructured":"Zannin ME, Birolo C, Gerloni VM et al (2013) Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow-up data from the italian registry. J Rheumatol 40(1):74\u201379","journal-title":"J Rheumatol"},{"issue":"4","key":"2960_CR54","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/RHU.0b013e3181a4f459","volume":"15","author":"A Zeft","year":"2009","unstructured":"Zeft A, Hollister R, LaFleur B et al (2009) Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 15(4):161\u2013164","journal-title":"J Clin Rheumatol"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00431-017-2960-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-017-2960-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-017-2960-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T06:58:47Z","timestamp":1503125927000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00431-017-2960-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,20]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["2960"],"URL":"https:\/\/doi.org\/10.1007\/s00431-017-2960-6","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,20]]}}}